Orkambi 125 mg

Orkambi 125 mg tablets contain ivacaftor, a medication used to treat cystic fibrosis. This oral medication is designed to improve lung function and reduce symptoms associated with the condition.

Orkambi 125 mg tablets are primarily used in the management of cystic fibrosis in patients who have specific genetic mutations. Ivacaftor, the active ingredient, works by helping the cystic fibrosis transmembrane conductance regulator (CFTR) protein function more effectively. This can lead to improved lung function and reduced symptoms such as coughing and shortness of breath. Orkambi is often prescribed as part of a comprehensive treatment plan for cystic fibrosis.

Common effects of Orkambi 125 mg tablets may include headaches, stomach pain, and dizziness. Some users might experience changes in liver function, so regular monitoring is advised. It's important to discuss any persistent or severe side effects with a healthcare provider.

Orkambi 125 mg tablets should be used with caution in patients with liver disease or a history of liver problems. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Orkambi 125 mg tablets may interact with certain medications, including those that are metabolized by the liver's cytochrome P450 enzymes. It is important to avoid grapefruit and grapefruit juice, as they can affect the metabolism of ivacaftor. Always consult a healthcare provider before starting or stopping any medication while taking Orkambi.